TABLE 1.
Baseline characteristics of included randomized trials.
| Study/References | Location | Number of patients | Multicenter center | Primary endpoint | Mortality reported | Maximum follow-up | Lost to follow-up (%) |
| IVUS versus CAG | |||||||
| Jakabcin et al. (21) | Czech Republic | 105/105 | NO | MACE | YES | 1.5 years | NA |
| AVIO, (22) | International | 142/142 | YES | post-procedure in lesion minimal lumen diameter | NO | 2 years | 3.2 |
| RESET, (23) | Korea | 269/274 | YES | MACE | YES | 1 year | 0 |
| MOZART, (24) | Brazil and Spain | 41/42 | NA | total volume contrast agent used | YES | 4 months | 0 |
| IVUS-XPL, (25) | Korea | 700/700 | YES | MACE | NO | 1 year | 5.0 |
| CTO-IVUS, (8) | Korea | 201/201 | YES | cardiac death | YES | 1 year | 0.2 |
| Tan et al. (26) | China | 61/62 | NO | MACE | NO | 2 years | NA |
| AIR-CTO, (1) | China | 115/115 | YES | in-stent late lumen loss | YES | 2 years | 1.7 |
| Wang et al. (27) | China | 38/42 | NO | MACE | NO | 1 year | 0 |
| ULTIMATE, (2) | China | 724/724 | YES | target-vessel failure | YES | 1 year | 0.3 |
| SURF, (28) | Australia | 688/700 | NO | Major bleeding and MACE | YES | 30 days | 3.4 |
| OCT/OFDI versus CAG | |||||||
| DOCTORS, (10) | France | 120/120 | YES | FFR at the end of the procedure | YES | 6 months | 0.4 |
| ROBUST, (29) | Czech Republic | 105/96 | YES | MACE | YES | 9 months | 11.4 |
| OPTICO BVS, (30) | Europe | 19/19 | YES | in-scaffold minimal lumen area | YES | 6 months | 0 |
| OPTIMUM, (3) | Japan | 56/54 | YES | percentage of malapposed struts | YES | 1 year | 4.5 |
| FFR/QFR versus CAG | |||||||
| FAME, (31) | International | 509/496 | YES | MACE | YES | 5 years | 13.9 |
| DKCRUSH-VI, (12) | China | 160/160 | YES | MACE | YES | 1 year | 0 |
| FAMOUS–NSTEMI, (4) | United Kingdom | 176/174 | YES | medical management | YES | 1 year | 0 |
| DEFER-DES, (5) | Korea | 114/115 | YES | MACE | NO | 5 years | 3.5 |
| Zhang et al. (32) | China | 110/110 | NO | MACE | YES | 1 year | NA |
| Quintella et al. (6) | Brazil | 34/35 | NO | MACE | YES | <12 months | 1.4 |
| FLOWER-MI, (33) | France | 586/577 | YES | MACE | YES | 1 year | 0.4 |
| FAVOR III China, (34) | China | 1913/1912 | YES | MACE | YES | 1 year | 0.5 |
| OCT/OFDI versus IVUS | |||||||
| Habara et al. (35) | Japan | 35/35 | NO | stent expansion | YES | in-hospital | 0 |
| OPINION, (36) | Japan | 412/405 | YES | target vessel failure | NO | 1 year | 1.2 |
| MISTIC-1, (37) | Japan | 54/55 | YES | in-segment minimum lumen area | YES | 3 years | 0.9 |
| OCT versus FFR | |||||||
| FORZA, (38) | Italy | 174/176 | NO | MACE | YES | 13 months | NA |
| OCT versus IVUS versus CAG | |||||||
| ILUMIEN III, (39) | International | 158/146/146 | YES | minimal stent area | YES | 1 year | 4.2 |
ACS, acute coronary syndrome; CAG, coronary angiography; FFR, fractional flow reserve; IVUS, intravascular ultrasound; MACE, major adverse cardiac events; OCT, optical coherence tomography; OFDI, optical frequency domain imaging; QFR, quantitative flow ratio.